Quarterly ResultAug 5, 2026, 07:12 AM
NewAmsterdam Pharma Q2 Net Loss Widens to $64.1M; Revenue Down 80.6%
AI Summary
NewAmsterdam Pharma reported a significant widening of its net loss for the second quarter of 2026, reaching $64.1 million, compared to $17.4 million in the same period last year. Revenue for the quarter also saw a substantial decline of 80.6% to $3.7 million. The company experienced increased research and development expenses and a decrease in cash and cash equivalents. Additionally, the company adopted an Employee Stock Purchase Plan and changed the valuation method for its Public Warrant liabilities.
Key Highlights
- Net loss for Q2 2026 widened to $64.1 million, up from $17.4 million in Q2 2025.
- Revenue for Q2 2026 decreased by 80.6% to $3.7 million from $19.1 million in Q2 2025.
- Research and development expenses increased by 51.4% to $41.7 million in Q2 2026.
- Cash and cash equivalents decreased to $424.2 million as of June 30, 2026.
- Total shareholders' equity decreased to $631.4 million as of June 30, 2026.
- Derivative warrant liabilities decreased to $54.5 million as of June 30, 2026.
- Company adopted an Employee Stock Purchase Plan (ESPP) effective July 1, 2026.
- Valuation method for Public Warrant liabilities changed from Level 1 to Level 2.
Price Impact
More from NAMS